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Abstract
Background: MCT-1 oncoprotein accelerates p53 protein degradation via a proteosome pathway. Synergistic
promotion of the xenograft tumorigenicity has been demonstrated in circumstance of p53 loss alongside MCT-1
overexpression. However, the molecular regulation between MCT-1 and p53 in tumor development remains
ambiguous. We speculate that MCT-1 may counteract p53 through the diverse mechanisms that determine the
tumorigenic outcomes.
Results: MCT-1 has now identified as a novel target gene of p53 transcriptional regulation. MCT-1 promoter region
contains the response elements reactive with wild-type p53 but not mutant p53. Functional p53 suppresses MCT-1
promoter activity and MCT-1 mRNA stability. In a negative feedback regulation, constitutively expressed MCT-1
decreases p53 promoter function and p53 mRNA stability. The apoptotic events are also significantly prevented by
oncogenic MCT-1 in a p53-dependent or a p53-independent fashion, according to the genotoxic mechanism.
Moreover, oncogenic MCT-1 promotes the tumorigenicity in mice xenografts of p53-null and p53-positive lung
cancer cells. In support of the tumor growth are irrepressible by p53 reactivation in vivo, the inhibitors of p53
(MDM2, Pirh2, and Cop1) are constantly stimulated by MCT-1 oncoprotein.
Conclusions: The oppositions between MCT-1 and p53 are firstly confirmed at multistage processes that include
transcription control, mRNA metabolism, and protein expression. MCT-1 oncogenicity can overcome p53 function
that persistently advances the tumor development.
Background
Mutations or loss of the tumor suppressor p53 gene
have been documented in more than 50% of human
cancers [1-3]. Functional p53 is involved in the regula-
tion of genomic integrity, growth arrest, DNA repair,
programmed cell death, and cell differentiation [3-5]. As
a transcription factor, p53 binds specifically to the con-
sensus DNA sequence consisting of two copies of the
10-bp motif 5’-RRRC(A/T)(T/A)GYYY-3’, in which R is
a purine and Y is a pyrimidine, separating by a 1-13
base pair (bp) junction [6-8]. These specific sequences
are recognized in the p53 regulatory genes, such as
Pirh2 [9], Cop1 [10], Waf-1/p21 [11], MDM2 [12], Bax
[13], and PCNA [14]. Numerous p53 downstream tar-
gets are implicated in tumor suppression. But Pirh2,
MDM2, and Cop1 are ubiquitin ligases implicated in
tumor development that mediate p53 degradation in a
proteosome manner [9,10,15]. The genome-wide ChIP
studies have also indentified the p53-regulatory genes
BCL2A1, PTK2 and VIM that associate with tumor for-
mation [16,17].
The activity of p53 exerts paradoxically anti-apoptotic
and pro-survival effects, which are essential for the
development of an organism and may turn p53 into a
tumor promoter. As a comprehensive guardian of gen-
ome integrity, p53 confers the survival-promoting
advantages of cancer cells [18]. More substantial evi-
dence have emerged that p53 protects cells from the
genotoxin-induced apoptosis [19-21]. Though p53
induces Bax activation and apoptosis, relocating the p53
protein to mitochondria does not trigger tumor cell
death, conversely grants apoptotic resistance to ionizing
radiation [22]. Moreover, p53 reduces the oxidation-
induced DNA damage and apoptosis [23-25]. Overall,
p53 has its dark side that enhances the cell surviving
mechanism and potentially inititates tumorigenicity.
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Exploration of p53 antagonists or p53 downstream tar-
gets which are implicated in tumorigenesis, is thus a
very important task.
MCT-1 (multiple copies in T cell malignancy 1) onco-
gene is highly expressed in the human lymphomas
[26,27]. Overexpression of MCT-1 promotes cell survi-
val, proliferation, checkpoint bypass, and anchorage-
independent growth [26,28,29]. Constitutively expressed
MCT-1 transforms normal breast epithelial MCF-10A
cells [30], and increases the tumorigenicity of breast
cancer MCF-7 cell xenografted mice, possibly through
promoting angiogenesis and anti-apoptosis [31]. MCT-1
protein interacts with the ribosome and associates with
the cap complex by the putative RNA-binding motif,
PUA domain [32,33]. Ectopic MCT-1 also promotes
translational initiation of many cancer-related mRNAs,
including BCL2L2, Cyclin D1, TFDP1, MRE11A and
E2F1 [34]. Furthermore, ectopically expressed MCT-1
decreases p53 mRNA levels and p53 protein stability
in vitro [35,36].
The regulations in opposition between p53 and MCT-
1 have now been verified in vitro and in vivo. The wild-
type p53 targeting the MCT-1 gene promoter could
affect the presentation of MCT-1 mRAN and protein.
Reciprocally, MCT-1 depresses p53 gene promoter,
mRNA stability, and protein function. Moreover, the
reactivation of p53 cannot restrain the MCT-1 tumori-
genic impacts on H1299 (p53 null) lung cancer cells
xenografted mice and the stimulation of p53 repressors
(MDM2, Pirh2, and Cop1). As well, the oncogenic
MCT-1 persistently promotes the xenograft tumorigeni-
city of A549 (p53 wild-type) lung cancer cells. These
data reveal that MCT-1 advances cellular malignancy
and tumorigenic potency independent of p53 status.
Results
MCT-1 gene and protein are downregulated by p53
To investigate whether p53 affected intrinsic MCT-1
gene activation, the non-small cell lung cancer H1299
(p53 null) cells were transfected with pCDNA vector
alone or pCDNA-p53 to rebuild p53 function (control +
p53, MCT-1 + p53). For examining the MCT-1 promo-
ter function, a 1.3 kb MCT-1 gene promoter segment
(-1301 to +37) was engineered into a pGL3-luciferase
basic vector. The pGL3-MCT-1 promoter construct was
then introduced into the control H1299 cells (control)
that expressed with the vector alone (pCDNA), the
wild-type p53 (pCDNA-p53), or the mutant p53
(pCDNA-p53mt135) (Figure 1A). Cells presenting wild-
type p53, the pGL3-MCT-1 luciferase activity was
depressed markedly to 60% of promoter activity of cells
without p53 (vector) (p < 0.0001). Conversely, the
pGL3-MCT-1 promoter activity was unchanged by the
mutant p53, revealing that only the functional p53
particularly deactivated the MCT-1 gene promoter.
Similar data was also presented in context of pLXSN-
MCT-1 expressed H1299 (MCT-1) that only wild-type
p53 affected MCT-1 promoter activity. To exclude the
possibility that p53 non-specifically obstructed the pro-
moter function, the 5’LTR promoter segment of pLXSN
was constructed into a pGL3-Luciferase basic vector.
Obviously, the p53 showed no effect on the reporter
activity of pGL3-5’LTR (Additional File 1A).
To further analyze the half-life (t1/2) of MCT-1 mRNA
in H1299 cell present or absent of p53, Actinomycin D
was used for inhibition of de novo gene transcription
(Figure 1B). Cellular RNA samples were then harvested
at the indicated intervals to measure MCT-1 mRNA
quantities by qRT-PCR study. Results indicated that the
intrinsic MCT-1 mRNA decayed faster in cells having
p53 (t1/2 = 3.1 h) (control + p53, filled square) than
those lacking p53 (t1/2 = 4.01 h) (control, open square).
As well, the MCT-1 gene expression was examined after
cells transfecting with pLXSN vector alone (control) or
pLXSN-MCT-1 (MCT-1). Similar to intrinsic MCT-1
mRNA turnover, p53 renovation also negatively regu-
lated the steady-state of ectopic MCT-1 mRNA that
decomposed rapidly (t1/2 = 3.5 h) (MCT-1 + p53, filled
triangle) comparing with p53 absent condition (t1/2 =
4.5 h) (MCT-1, open triangle). The effect of p53-depen-
dent destabilization of MCT-1 mRNA stability was
inhibited as MCT-1 mRNA was much stable in the
MCT-1 + p53 cells (t1/2 = 3.5) than the control + p53
cells (t1/2 = 3.1), possibly ectopic MCT-1 performing a
negative impact on p53 role.
By quantifying the overall MCT-1 mRNA levels with
qRT-PCR analysis (Figure 1C), MCT-1 mRNA levels in
the p53 gene-restored H1299 cells (control + p53) were
found to be decreased to 71% of that of sample without
the p53 expression (control + vector). Consistent with
decrease in cellular MCT-1 mRNA levels by p53, the
levels of exogenic MCT-1 mRNA (MCT-1 + p53) (6.78)
also dramatically reduced to 54% of that of the vector
controls (MCT-1 + vector) (12.54) as well. These data
demonstrate that the p53 reactivation can effectively
repress MCT-1 gene presentation.
Further analysis was examined whether p53 reduction
conversely improved MCT-1 expression in normal breast
epithelial MCF-10A cells with wild-type p53 and regular
genetic background (Figure 1D). MCT-1 protein levels
were detected by the specific Ab against a synthetic pep-
tide (a.a. 72-88) of MCT-1 polypeptide. Following etopo-
side (ETO) genotoxin treatment for 4 h, cellular p53 was
accumulated and functionally activated. MCT-1 amount
was found to be a 2-fold increase after p53 silencing (p53
shRNA) relative to the non-silence control (MOCK)
(lanes 1 vs. 3). Moreover, ectopic MCT-1 protein
(V5-tag) was recognized by the V5-epitope Ab that
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showed a 1.62-fold elevation after p53 knockdown com-
parative to the non-silence group (lanes 2 vs. 4). These
validate that p53 presence actually counteracts MCT-1
protein production.
The unexpected data indicated that intrinsic MCT-1
protein was dramatically inhibited after ectopic MCT-1
expression (Figure 1E). As well, the autoregulation of
MCT-1 gene presentation was identified as the pGL3-
MCT-1 promoter activity was diminished by ectopic
MCT-1 to 67% of that of control group. Even so, the
entire MCT-1 protein amounts (ectopic plus intrinsic)
still promoted to a 2.2-fold induction as compared with
control group. These data establish for the first time
that MCT-1 controls itself, via a feedback loop involving
the promoter downregualtion.
Interaction of p53 with the MCT-1 promoter region
MCT-1 promoter region was searching for the consensus
p53-binding element, 5’-RRRC(A/T)(T/A)GYYY-3’, using
the NTI vector program. Six potential p53-binding sites
were identified at the MCT-1 promoter region that located
between nucleotides (nt.) -1301 and -801 (Figure 2A).
ChIP analysis was studied whether the MCT-1 promoter
DNA associated with the activated p53 protein under
ETO genotoxic stress in MCF-10A cells (Figure 2B).
Immune complex of p53 antibody (p53 Ab-IP) were
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Figure 1 MCT-1 gene and protein expressions are decreased by p53. The pGL3-MCT-1 promoter construct was transiently transfected into
H1299 (p53 null) cells. (A) Reduced luciferase activity of the pGL3-MCT-1 reporter was identified when H1299 cells (control) expressed the wild-
type p53 but not the mutant p53. Similar effects were recognized in context of MCT-1 overexpression (MCT-1) (B) The half-life (t1/2) of MCT-1
mRNA was analyzed by qRT-PCR after actinomycin D (5 μg/ml) treatment for the indicated time. Quantitative data was acquired as normalized
with 18S rRNA levels. Cellular MCT-1 mRNA turnover was greater induced by p53 expression (control + p53) than p53 null condition (control).
The exogenic MCT-1 mRNA decayed quickly in p53 renovation (MCT-1 + p53) versus (vs.) without p53 expression (MCT-1). (C) As determined
with qRT-PCR analysis, the p53 knock-in H1299 moderately depressed intrinsic MCT-1 mRNA levels (control vs. control + p53). As well, the
exogenic MCT-1 mRNA levels were significantly depressed by p53 (MCT-1 vs. MCT-1 + p53). (D) MCF-10A cells were under ETO genotoxic stress
for 4 h. The ectopic (V5-tag) and intrinsic MCT-1 protein in MCF-10A (p53-proficient) cells were reversely elevated because p53 gene silence (p53
shRNA) relative to MOCK experiment. (E) Ectopic expression of MCT-1 reduced pGL3-MCT-1 promoter activity together with decrease in intrinsic
MCT-1 protein. The overall cellular MCT-1 protein amounts (intrinsic plus ectopic) were more than a 2.2-fold elevation after MCT-1 induction.
Statistics were analyzed with Student’s t test. ***p < 0.0001.
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PCR-amplified with the primers (Additional File 2) for the
MCT-1 promoter region that correspondingly produced
DNA fragment sizes of 166, 173 and 199 base pair (bp).
Conversely, the nonspecific (NS) site located at the MCT-
1 coding region (nt. 1~149) was undetectable in the p53
Ab-IP complex. The RNA polymerase II specifically recog-
nized GAPDH gene as a positive control, but no DNA
associated with normal IgG. Using a qPCR analysis to
quantify ChIP results, the 166 and 199 bp locations exhib-
ited higher associations with p53 than that of the 173 bp
region (p < 0.002) (Figure 2C), indicating their differential
connections with p53 protein. Furthermore, the parental
(p53 null) or the p53 gene restored H1299 cells
(p53-reconstituted) were conducted with ChIP studies
(Figure 2D). The MCT-1 promoter DNA was only detect-
able in the p53-IP complex of the p53-reconstituted sam-
ple but not in the parental group. Though no p53
repressor element (p53TRE) is noticed in the MCT-1
promoter region, the relation of p53 protein with MCT-1
promoter may obstruct MCT-1 gene transcription.
Electrophoretic-mobility shift assay (EMSA) was inves-
tigated whether p53 protein closely interacted with the
MCT-1 promoter sites. Biotin-labeled probes (166, 173,
and 199 bp), covering the promoter region from -1301
to -801 (Figure 2A), were prepared and incubated with
nuclear extracts (NE) from MCF-10A cells after etopo-
side (ETO) treatment that stimulated and stabilized p53
protein. The biotinylated 166 bp probe formed a com-
plex with the nuclear protein as indicated by a mobility
shift (Figure 3A, lane 3). This specific DNA-protein
complex was dramatically competed by a 100-fold
excess of the p53 consensus oligonucleotides (lane 4)
but not the mutant p53-responsive element (lane 5).
Furthermore, p53 existence in the complex was proved
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Figure 2 MCT-1 promoter associates with p53. (A) Six putative p53-binding sites on the MCT-1 promoter region are illustrated. The primers
for ChIP assays are indicated by 166, 173 and 199 bp on the MCT-1 promoter region with the horizontal arrows. (B) Following the genotoxic
stress, MCF-10A genomic DNA was immunoprecipitated (IP) with p53 and RNA polymerase II Ab. The original input and the Ab-IP complexes
were amplified by a conventional PCR analysis with the primers for MCT-1 promoter, MCT-1 coding region, or GAPDH gene. MCT-1 promoter
DNA was identified by primers specific for the 166, 173, and 199 bp fragments in the IP complex of p53 Ab (lanes 6, 8, 10) but not normal IgG
(lane 4). MCT-1 coding region was undetectable in the p53-IP complex (lane 3). The GAPDH gene interacting with RNA polymerase II was
recognized as a positive control (lane 1). (C) In quantitative PCR (q-PCR) comparison, the relative values were normalized with the original input
and then compared with the non-specific MCT-1 coding region (NS site). (D) MCT-1 promoter DNA fragment (166 bp) was detected only in the
p53-IP complex of the p53-restored H1299 cells under the genotoxic stress. Statistical analysis was done with the Student’s t test. **p < 0.002;
***p < 0.0001.
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by generating a super-shifted band after incubation with
the p53-specific antibody (lane 6). But, no obvious com-
plex formed between the p53 Ab and the DNA probe
alone (lane 1).
On the other hand, the biotinylated 173 bp probe
revealed a specific interaction with the nuclear protein
(Figure 3B, lane 2), which was greatly attenuated by adding
a 100- or 200-fold excess of p53 consensus oligonucleotide
(lanes 3 and 4). A super-shifted band was evidently
induced by the p53 Ab, confirming the presence of p53
protein in the complex (lane 6). On the contrary, the
DNA-protein complex was unable to be depleted by the
mutant p53-responsive element (lane 5). As well, no
detectable complex was produced between the p53 Ab
and the DNA probe alone (Figure 3B, right panel).
Another DNA-protein complex was recognized while
the nuclear extracts reacting with the biotinylated 199 bp
probe (Figure 3C, lane 2). This complex was also signifi-
cantly repressed by a 100-fold excess of the wild-type p53
consensus oligonucleotide (lane 3), but it was insignifi-
cantly contended by the mutant p53-responsive element
(lane 4). A super-shifted mobility caused by the p53 Ab
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Figure 3 Binding of p53 to the MCT-1 promoter region. EMSA was conducted by incubating the MCT-1 promoter probes with nuclear
extracts of MCF-10A cells after the genotoxin (ETO) treatment. (A) The biotin-labeled 166 bp probe formed a complex with the nuclear protein
(lane 3). This complex was partially depleted by the wild-type (lane 4) but not by the mutant (lane 5) p53-responsive elements in a 100X excess
concentration. The presence of p53 in complex was confirmed by inducing a super-shift complex with p53 Ab (lane 6). No specific interaction
between the probe and p53 Ab was recognized (lane 1). (B) The biotin-labeled 173 bp probe formed a DNA-protein complex with the nuclear
protein (lane 2). This complex was partially reduced by the wild-type competitor at concentrations of 100X excess (lane 3) and 200X excess (lane
4), but it was not depleted by the mutant competitor at a concentration of 100X excess (lane 5). The presence of p53 in complex was
confirmed by the p53 Ab inducing a super-mobility shift (lane 6). No specific complex formed between the probe and p53 Ab (right panel). (C)
The biotin-labeled 199 bp probe interacted with the nuclear protein (lane 2). This DNA-protein complex was specifically interrupted by wild-type
(lane 3) but not the mutant p53-responsive competitor at a concentration of 100X excess (lane 4). A super-shift band was identified as p53 Ab
reacted with the DNA-protein complex (lane 5). Again, no particular complex produced among the probe and p53 Ab (right panel).
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clarified p53 being in the DNA-protein complex (lane 5).
Moreover, no specific DNA-protein complex was gener-
ated between p53 Ab and the DNA probe (Figure 3C,
right panel). These data have evidently proved that p53
protein interacts with the promoter ofMCT-1 gene.
MCT-1 inhibits p53 promoter activation and protein
expression
ChIP assay was again evaluated if the MCT-1 protein reci-
procally associated with p53 gene promoter (Figure 4A).
The p53 promoter-specific primers ranging from -420 to
-84 were identified whether the p53 promoter DNA
contained in the IP complex of MCT-1 Ab. In a PCR
amplification analysis, approximately 8.9% of p53 promo-
ter DNA was discovered in MCT-1 immune complex (IP).
Control experiments had identified that GAPDH gene
specifically associated with RNA polymerase II, but no
genomic DNA was coupled with a normal IgG. Different
from p53 specific binding with the MCT-1 promoter
DNA (Figure 3), no interaction was detected between the
p53 promoter DNA and MCT-1 protein in the EMSA
study (data not shown). It is possible that MCT-1 could
cooperate with other undisclosed molecule(s) that closely
interact with the p53 gene promoter.
Figure 4 MCT-1 decreases p53 promoter function and protein expression. (A) The primers of p53 promoter region (-420 to -84) were
hybridized with the ChIP complex. The p53 promoter DNA specifically contained in the IP complex of MCT-1 Ab but not normal IgG. (B)
Luciferase activity of the pGL3-p53 promoter was depressed by ectopic MCT-1 (MCT-1) compared with control H1299 (control). (C) The pGL3-p53
promoter was conversely activated while MCT-1 silencing in H1299 context. (D) The half-life of exogenic p53 mRNA was decreased in ectopic
MCT-1 group (MCT-1 + p53) relative to the corresponding control (control + p53) (P < 0.0001). (E) The overall p53 mRNA productions in the
p53-restored H1299 cells were declined evidently in ectopic MCT-1 background (MCT-1 + p53). (F) Upon etoposide (ETO) exposure for 4 h,
ectopic MCT-1 reduced the p53 functional activation of p21 (lanes 3 vs. 4). (G) The shRNA interference of intrinsic MCT-1 in MCF-10A cells
conversely stimulated p53 and p21 proteins upon ETO treatment for 30 min. (H) The effects of wild-type MCT-1 (WT) and MCT-1 mutants that
were directly mutated on Serine 118 residue (S118) to Alanine (S118A), Aspartic acid (S118D), and Glutamic acid (S118E) were studied. The
dephosphorylation mutant (S118A) significantly improved the pGL3-p53 promoter function, but pGL3-p53 promoter was still repressed by cells
expressing the phosphorylation-mimetic MCT-1 (S118D and S118E) and wild-type MCT-1. Statistical data was assessed with the Student’s t test.
**p < 0.002; ***p < 0.0001.
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The proximal p53 promoter region (-188 to +12) con-
tains a full promoter activity in the response to DNA
damage [37,38]. To study whether ectopic MCT-1
antagonized p53 promoter activity, the p53 promoter
DNA (-188 to +23) segment was cloned into the pGL3-
Luc basic vector and then transfected into H1299 cells.
The luciferase activity of pGL3-p53 promoter in ectopic
MCT-1 group was decreased approximately to 70% of
the respective control group (control) (Figure 4B), indi-
cating that MCT-1 functionally inactivated p53 promo-
ter. The activity of CMV promoter of pCDNA3.1 that
was cloned into the pGL3-Luc basic vector was not
affected by the MCT-1, excluding the possibility that
ectopic MCT-1 non-specifically affected the promoter
function (Additional File 1B).
To analyze if MCT-1 status directly involved in p53
gene deactivation, MCT-1 gene was knocked down by
MCTS1 shRNA in H1299 cells that reduced cellular
MCT-1 protein to different degrees (high, medium, low)
(Figure 4C). By contrast with suppression of MCT-1
protein levels, the pGL3-p53 promoter activity was pro-
gressively improved. As compared with low p53 promo-
ter activity in high MCT-1 context, the reporter activity
was conversely elevated up to a 2-fold induction while
MCT-1 declined significantly. These verify that MCT-1
plays a critical role in regulation of p53 gene promoter.
We speculated that MCT-1 also repressed the p53
gene reactivation in H1299 cells, the metabolism of exo-
genic p53 mRNA was analyzed after de novo gene tran-
scription being inhibited by actinomycin D (Figure 4D).
The remaining of p53 mRNA quantity was assessed
with qRT-PCR analysis at each time point. Unlike exo-
genic p53 mRNA decayed quickly under MCT-1 onco-
genic influence (t1/2 = 2.66 h) (MCT-1 + p53, close
square), the p53 mRNA was relatively stable in control
group (t1/2 = 4.28 h) (control + p53, open triangle).
Further assessment with qRT-PCR study, we found that
the total p53 mRNA quantities in ectopic MCT-1 cells
(MCT-1 + p53) were dropped to 68% of that of controls
(control + p53) (Figure 4E). Taken together, these
results firstly illustrate that MCT-1 inhibits the overall
p53 mRNA expression by decreasing p53 promoter
function and p53 mRNA stability.
Consistent with the p53 gene deactivation and p53
mRNA reduction (Figure 4B-4E), the ectopic p53 that
functionally stimulated the p21 protein expression upon
etoposide (ETO) exposure for 4 h was greatly sup-
pressed by MCT-1 (MCT-1 + p53) relative to the con-
trol H1299 (control + p53) (Figure 4F, lanes 3 vs. 4).
Confirmative data also revealed that MCTS1 shRNA
interference reversely elevated p53 and p21 proteins in
MCF-10A cells exposure to ETO (30 min) (Figure 4G).
Thus, MCT-1 overexpression effectively counteracts the
p53-p21 signaling function that is reversible after MCT-1
knockdown.
MCT-1 overexpression activating the extracellular sig-
nal-regulated kinase activity (ERK) is link with p53
degradation (35). To test the functional domain respon-
sible for p53 promoter deactivation (Figure 4H), the Ser-
ine 118 (S118) residue of the potential MAPK kinase
phosphorylation site on MCT-1 protein was specifically
mutated to Alanine (S118A). As well, MCT-1 (S118)
residue was modified to Glutamic acid (S118E) and to
Aspartic acid (S118D) that were mimetic to the phos-
phor-S118 MCT-1. Surprisingly, only the S118A mutant
restored the p53 promoter activity significantly, but the
phosphorylation-mimetic MCT-1 (S118E and S118D)
still decreased p53 promoter to an extent comparable to
wild-type (WT). These suggest that the serine 118 resi-
due on MCT-1 is essential and sufficient for inhibition
of p53 promoter function.
MCT-1 oncogenic effects in p53-dependent and
p53-independent manners
To evaluate the cooperative impact of p53 loss and
MCT-1 oncogenicity on cell survival (Figure 5A), MCF-
10A cells induced with (MCT-1) or without MCT-1
(control) were subsequently knocked down cellular p53
protein (control-p53 and MCT-1-p53). Following expo-
sure to hydrogen peroxide (H2O2, 5 μM) for 24 h, cell
death was analyzed with FITC-Annexin V flow cytome-
try. Ectopic MCT-1 cells showed a lower apoptotic out-
come (20%) than that was detected in p53-proficient
controls (44%). After p53 loss, cell death induced by the
oxidative damage was promoted equally in control-p53
(67%) and MCT-1-p53 (64%) situations. These indicate
that MCT-1 protects cells from the oxidative stress rely-
ing on p53 function.
On the other hand, a radiomimetic agent, Bleomycin
(BLM) was treated MCF-10A cells (Figure 5B). Death
events were not significantly induced in p53 proficient
background (control and MCT-1). But, cells deficient
with p53 (control-p53 and MCT-1-p53) increased inci-
dence of apoptosis upon BLM exposure. Even so, the
apoptotic populations were still less detected in MCT-1-
p53 group (14.9%) than control-p53 set (26.0%), reveal-
ing that MCT-1 protected cells from BLM genotoxicity
independent of p53 function.
Cell migratory ability was moreover investigated by
Fluorimetric cell migration assay (Figure 5C). While cul-
turing in the complete media, cell mobility was notably
enhanced in p53 knockdown (control-p53 and MCT-1-
p53) but unaffected by inducing MCT-1. Cell motility
mainly enhanced by loss of p53 function may be related
with Rho signaling pathway that controls actin cytoske-
leton organization as literatures demonstrate [39].
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To confirm MCT-1 tumorigenic potency in a p53
wild-type background, A549 lung adenocarcinoma cells
ectopically expressed MCT-1 oncogene also slightly sup-
pressed p53 accumulation in the response to ETO geno-
toxin (Figure 5E). Following A549 cells subcutaneously
injected into the nude mice, the tumorigenic results had
evidently proved that MCT-1 oncogene strongly pro-
moted the tumor development to a 12.8-fold increase in
comparison with the control A549 xenografts (Figure 5D).
Therefore, MCT-1 oncogenicity could go beyond p53
function in the tumorigenic development.
MCT-1 promotes tumorigenicity independent of p53
status
It was unidentified whether wild-type p53 gene reconstitu-
tion in the p53 null background relieved MCT-1
oncogenicity. The impact of p53 restoration on chromo-
some copy number was surveyed by a cytogenetic study
[36]. The intrinsic gene mutations (chromosome amplifi-
cation) in H1299 background (copy number = 101) did
not obviously improve after p53 gene reconstitution (copy
number = 97) or change as MCT-1 overexpressed (copy
number = 97). These suggest that p53 reactivation prob-
ably cannot alter MCT-1 tumorigenic outcomes.
To explore whether MCT-1 oncogene continually antago-
nizes p53 function in vivo, different types of H1299 cells
(control, MCT-1, control + p53, MCT-1 + p53) were subcu-
taneously inoculated into athymic BALB/c mice. The xeno-
graft tumor burdens were enhanced dramatically in the
mice engrafted with MCT-1 and MCT-1 + p53 expressed
cells as compared with their corresponding control and con-
trol + p53 cells (p < 0.0001) (Figure 6A). Moreover, the
Figure 5 MCT-1 oncogenicity in p53-dependent and p53-independent manners. (A) Apoptotic results were analyzed with Annexin V
staining. MCF-10A cells containing p53 (control and MCT-1) or silencing p53 (control-p53 and MCT-1p53) were exposed to H2O2 for 24 h. MCT-1
prevented cell death in a p53-dependent manner. (B) Apoptotic events were insignificant in p53 proficient cohorts (control and MCT-1) as cells
treated with BLM for 24 h. At p53 reduced condition, ectopic MCT-1 decreased apoptotic effect (MCT-1-p53), contrasting with high apoptotic
events in control group (control-p53). (C) Fluorimetric Cell Migration Array Kit was analyzed cell movement ability induced by p53 deficiency but
unaffected by MCT-1 status. (D) The A549 (p53 wild-type) lung cancer cells expressed MCT-1 oncoprotein still demonstrated with higher tumor
burdens than control xenografts. (E) Oncogenic MCT-1 slightly reduced p53 accumulation after etoposide (ETO) treatment.
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MCT-1 xenografts produced drastically larger tumors con-
taining with higher hemoglobin levels (p < 0.0001) and vas-
cular counts (p < 0.0001) than those were identified in the
control and control + p53 xenografts. Though p53 function-
ally activated p21 expression (Figure 4F), the wild-type p53
gene transfer still unsuccessfully repressed tumor growth in
ectopic MCT-1 background that concomitantly increased in
micro-vascularization as evaluated with the endothelial
marker CD31 immunohistology staining (Figure 6B). As a
result, the tumorigenicity and angiogenecity are not sup-
pressed by p53 renovation; probably due to p53 only func-
tion effectively in the early tumor initiation stage. Once the
tumors have developed, p53 activation disables to repair the
genetic mutations and control the tumor growth.
The interrelation between p53 and MCT-1 in the tumors
were subsequently verified by immunohistochemistry study
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Figure 6 Reactivation of p53 cannot prevent MCT-1 tumorigenicity. (A) Different types of H1299 cancer cells (control, MCT-1, control + p53,
MCT-1 + p53) were inoculated into the athymic nude mice. As indicated with CD31 immunostaining analysis, the vascular index (capillaries/field)
was calculated by six randomly selected fields from each tumor biopsy. Tumor weights, hemoglobin amounts, and capillary densities were
promoted in the MCT-1 and MCT-1 + p53 xenografts. (B) Immunohistology study of the tumors with CD31 Ab revealed a higher density of
microvessels (indicated with arrows) in the MCT-1 and MCT-1 + p53 xenografts than those identified in the control and control + p53
xenografts. (C) Immunohistology data indicated the proteins (brownish) and H&E counterstaining (blue) in the tumors. The basal levels of MCT-1
protein expressed in control and control + p53 samples (a, c). MCT-1 proteins were intensively enhanced in the ectopic MCT-1 tumors (b),
whereas the MCT-1 + p53 tumors reduced in MCT-1 concentration (d). The control and MCT-1 tumors were p53 null (e, f). Lower p53 levels
were noticed in the MCT-1 + p53 tumors (h) than that of the control + p53 xenografts (g). Cop1, Pirh2 and MDM2 were all enriched in the
MCT-1 tumors (j, n, l, p, r). MDM2 was also enriched in the control + p53 xenografts (s), but it was dramatically decreased in the MCT-1 + p53
xenografts (t). (D) The p53 protein was reduced by ectopic MCT-1 in the tumors (lanes 3 vs. 4). Similarly, intrinsic and ectopic MCT-1 quantities
were all decreased by p53 restoration (lanes 2 vs. 4). MDM2 levels were promoted after MCT-1 increment (lanes 1 vs. 2) or p53 reactivation
(lanes 1 vs. 3). But, MDM2 was comparatively reduced in the concomitant increase of p53 and MCT-1 (MCT-1 + p53) (lanes 3 vs. 4). (E) Consistent
with the tumor results, H1299 cells expressing MCT-1 significantly improved MDM2 protein levels (lanes 1 vs. 2), but MDM2 was rather decreased
in MCT-1 + p53 sample than control + p53 group. Pirh2 and Cop1 amounts were persistently enriched in the MCT-1 and MCT-1 + p53
backgrounds.
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(Figure 6C, a-t). Consistent with in vitro cellular results,
MCT-1 was also decreased markedly in the tumors with
p53 expression (MCT-1 + p53) (d). However, MCT-1 was
produced highly in the tumors without p53 (MCT-1) (b).
Though p53 was greatly restored in the H1299 background
(control + p53) (g), it was still comparatively reduced
because ectopic MCT-1 induction (MCT-1 + p53) (h).
Intriguingly, the p53 suppressors, Cop1 and Pirh2, were sti-
mulated predominantly in ectopic MCT-1 background (j,
n, l, p). Although MDM2 amounts were significantly
enhanced either by ectopic MCT-1 (MCT-1) (r) or by p53
restoration (control + p53) (s), the p53-mediated MDM2
induction in tumors was declined strikingly while simulta-
neously expressing MCT-1 and p53 (MCT-1 + p53) (t).
These protein expressions were furthermore inspected
in the tumors (Figure 6D). Due to p53 influence, lower
intrinsic and ectopic MCT-1 levels were detected in
MCT-1 + p53 tumors than in MCT-1 tumors (lanes 2
vs. 4). On the other hand, less p53 quantities observed
in the MCT-1 + p53 tumors than in control + p53 ones
(lanes 3 vs. 4). These indicate that MCT-1 works against
p53 in the tumor development. Consistent with the
findings in MCF-10A (Figure 1E), the auto-regulation of
MCT-1 was manifestly detected in vivo because endo-
genic MCT-1 decreased in quantity as ectopic MCT-1
expressed (lanes 1 vs. 2).
MDM2 oncogene is trans-activated by p53, functioning
as an E3 ubiquitin ligase to promote p53 degradation
[40]. Our results had shown that MDM2 quantities were
remarkably elevated in the MCT-1 xenografts as com-
pared with the control H1299 xenografts (lanes 1 vs. 2).
Even though MDM2 was promoted in the p53 renovation
(control + p53) (lanes 1 vs. 3) (Figure 6D), the extent of
MDM2 induced by p53 became insignificant when exo-
genic MCT-1 suppressed p53 action on MDM2 stimula-
tion (lanes 3 vs. 4). As well, ectopic MCT-1 intensified
Pirh2 and Cop1 productions that potentially destabilized
p53 protein (lanes 1 vs. 2). Likewise, the appearances of
MDM2, Pirh2, and Cop1 in the H1299 cellular context
were equivalent with their manifestations in tumors
(Figure 6E). Stimulations of MDM2, Pirh2, and Cop1
could explain how oncogenic MCT-1 attenuates p53 pro-
tein accumulation and tumor-suppressive role during
tumor development as the literatures report [41-43].
Supportive evidence was acquired from qRT-PCR ana-
lysis as well. MCT-1 mRNA levels in H1299 xenograft
tumors were considerably decreased by p53 reactivation
(Figure 7A) (MCT-1 vs. MCT-1 + p53, p < 0.0001). On
the other hand, when the p53 gene was transferred into
H1299 cells, p53 transcripts were dramatically sup-
pressed by ectopic MCT-1 (Figure 7B) (control + p53
vs. MCT-1 + p53, p < 0.0001). Unlike p53 gene deacti-
vation, MDM2 mRNA levels were somewhat induced by
ectopic MCT-1 (Figure 7C) (control vs. MCT-1, p <
0.0001). Though MDM2 transcripts were promoted in a
p53-dependent mode, this consequence apparently
decreased when MCT-1 inhibited p53 function (control
+ p53 vs. MCT-1 + p53, p < 0.0001). Differently, the
transcripts of Pirh2 and Cop1 genes constitutively pro-
moted by ectopic MCT-1 were only moderately affected
by p53 status (Figure 7D and 7E). Upregulation of
MDM2, Pirh2, and Cop1 gene molecules provide other
lines of evidence that MCT-1 downregulates p53 in
tumorigenic process at the transcriptional stage.
In support of the tumorigenic outcomes, the phos-
phor-activation of AKT and MAPK were found to be
enhanced in MCT-1 + p53 xenograft tumors relative to
the other cohorts (control, control + p53, MCT-1)
(Additional File 3A). Additionally, the integrin-b4 was
enriched particularly in MCT-1 + p53 xenograft tumors.
Furthermore, the molecules involving in the oncogenic
potential, H-Ras and HIF-1a mRNA levels, all showed
approximately 1.6-fold increases in MCT-1 + p53
xenografts compared with those in the control + p53
xenografts (Additional File 3B). Stimulations of these
anti-apoptotic molecules, which can enhance cancer cell
proliferation and survival mechanisms, emphasize that
the p53 reactivation under MCT-1 oncogenic stress fails
to slow down the tumor development.
Discussion
The antagonism between MCT-1 oncogene and p53
tumor suppressor
MCT-1 oncogene is a dangerous foe to p53 function,
playing multiple roles in promoting chromosome
instability and tumor growth [36]. Constitutively activat-
ing MCT-1 decreases p53 protein via a proteasome
pathway [35]. We now demonstrate that MCT-1 reduces
p53 mRNA levels accompanied with p53 gene promoter
inactivation and p53 mRNA destabilization, which well
correspond to inhibit p53-p21 pathway (Figure 4B-4F).
Conversely, MCT-1 gene interference stimulates p53
gene promoter and improves p53-p21 expression (Figure
4C and 4G). Moreover, the original results have also
demonstrated that p53 reciprocally interacts with the
MCT-1 gene promoter that potentially suppresses
MCT-1 oncogenicity in a feedback mechanism (Figure
2B-2D and Figure 3).
The mutual counteractions between p53 and MCT-1 at
the gene and protein stages are comparable to the negative
regulation between MDM2 and p53 [44,45]. As well, the
reciprocated transcriptional repression between MCT-1
and p53 resembles the mechanism of Twist oncogenic
activity that obstructs the p53 tumor-suppressive function
[46]. Another intriguing finding is that the induction of
MCT-1 exerts a self-directed inhibition on intrinsic MCT-
1 protein (Figure 1D-1E, and 6D), by which the overall
MCT-1 protein levels can be systematically controlled
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using an autonomous regulation in its promoter function
(Figure 1E). The integral self-control could determine the
steady state of MCT-1 activity that may critically regulate
cell growth or tissue homeostasis. Similar effect has been
identified that Myc overexpression contributes to tumori-
genesis and myc expression is controlled through an auto-
regulatory circuit in non-transformed cells, by which
elevated Myc protein amounts lead to down-regulation of
myc transcription [47]. As well, overexpression of c-myc
gene leads to a significant decrease in endogenous N-myc
levels [48].
Reactivation of p53 cannot suppress MCT-1 tumor-
promoting effect
The tumor promotion in MCT-1 expressed H1299
xenografts represents the synergistic consequences of
p53 null and MCT-1 induction (Figure 6). Our data
have demonstrated that p53 reactivation cannot com-
promise the tumorigenic results induced by MCT-1
oncogene. MCT-1 + p53 xenograft mice thus develop
significantly larger tumors with higher hemoglobin levels
and micro-vessel density than the other xenograft
tumors (control, MCT-1, control + p53). We have pre-
viously shown that p53 gene add-in cannot rescue the
p53-deficient cells from MCT-1 oncogenic impact on
genome destabilization, but actually increases incidence
of aneuploidy from 42.8% to 95% [36]. Thus, p53 reno-
vation fails to inhibit MCT-1-induced aneuploidization
that could predispose to many carcinogenic endpoints as
the documents report [49]. Another important fact is that
MCT-1 oncogene confers cellular resistance to the oxida-
tive pressure depending on p53 function (Figure 5A). In
the other way, the genotoxn-induced cytotoxicity is
reduced particularly when p53 is abrogated in ectopic
MCT-1 cells (Figure 5B). But independent of MCT-1
function, cell migratory ability is promoted predominantly
by p53 deficiency (Figure 5C), which could be coupled
with the signaling activation of Rho pathway [39].
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Figure 7 MCT-1 deactivates p53 but activates p53 inhibitors in tumor development. H1299 tumor biopsies were subjected to qRT-PCR
analysis. (A) MCT-1 mRNA levels in the MCT-1 + p53 xenograft tumors were decreased comparative to the MCT-1 xenografts. (B) The p53 mRNA
levels in the tumors were significantly declined in the MCT-1 + p53 xenografts relative to the control + p53 xenografts. (C) MDM2 mRNA
amounts were moderately increased by ectopic MCT-1 and further promoted by p53 restoration. Low MDM2 mRNA levels were presented that
was probably due to ectopic MCT-1 depress the p53 function. (D-E) Pirh2 and Cop1 mRNA levels were constitutively enhanced by oncogenic
MCT-1 in a p53-independent manner. Statistical analysis was performed with the Student’s t test. ***p < 0.0001.
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Regardless of p53 function, the tumor-promoting conse-
quence is still largely promoted in A549 (p53 wild-type)
lung cancer cells with a constitutive activation of MCT-1
(Figure 5D), further revealing that MCT-1 oncogenicity
could overcome p53 action in the tumor development.
The p53 inhibitors are stimulated in MCT-1 oncogenic
background
MCT-1 synergistically induces the oncogenic molecules
in the p53 deficient background, which could be impor-
tant for cell malignant transformation (Additional file
3). The biochemical and genetic information all support
that ectopic MCT-1 induces tumor promotion accompa-
nied with the enrichment of MDM2, Pirh2 and Cop1 in
the tumors (Figure 6C-6D and 7C-7E), moreover
explaining why p53 knock-in cannot suppress MCT-1
tumorigenic effects. In a p53-dependent manner, esca-
lating p21 and MDM2 levels have been demonstrated
that p53 restoration indeed actively regulates its down-
stream targets (Figure 4F and 6D-6E). Likewise, the
reactive p53 capably depresses MCT-1 protein in the
MCT-1 + p53 xenograft tumors (Figure 6C-6D).
Though MDM2 stimulated by p53 reconstitution, the
MCT-1 inhibitory impact on p53 expression is also
reflective to decline MDM2 gene and protein in MCT-1
+ p53 xenografts (Figure 6C-6D, 7C). Furthermore,
MCT-1 dramatically enhances Pirh2 and Cop1 gene
expressions that could eventually contribute to p53
destabilization (Figure 7D-7E). Overall, MCT-1 onco-
genicity competently surpasses p53 tumor-suppressive
ability that abolition of MCT-1 tumorigenic strength
through gain of p53 function becomes impossible.
Ectopic MCT-1 enhances p53 negative regulators that
can decline p53 function in tumor prevention in vivo.
These negative influences as well reflect to upregulate
MCT-1 promoter, MCT-1 mRNA stability, and overall
MCT-1 mRNA amounts in vitro. MCT-1 promoter func-
tion reduced by wild-type p53 shows somewhat improve-
ment in cells expressing MCT-1 (0.71) relative to control
group (0.6) (Figure 1A), potentially because ectopic MCT-1
reduces the p53 depressing effect. In evaluation of MCT-1
mRNA turnover (Figure 1B), the p53-dependent suppres-
sion on MCT-1 mRNA stabilization is reduced by ectopic
MCT-1 that MCT-1 mRNA is more stable in MCT-1 +
p53 sample (t1/2 = 3.5) than control + p53 group (t1/2 = 3.1)
(p < 0.001). Besides, the overall MCT-1 mRNA levels in
ectopic MCT-1 sample are much more enhanced (6.78)
than control group (0.71) (Figure 1C). This is partly due to
ectopic MCT-1 stimulate p53 inhibitors that can cancel the
p53-dependent suppression on MCT-1 transcription.
Genetic evidence has implicated that a6b4 integrin
signaling in promoting tumor angiogenesis and invasion
[50]. These can be enhanced by HIF-1a and Ras up-
expression as well [51-54]. A selective enhancement of
pro-survival molecules (Integrin-b4, p-AKT, p-MAPK,
H-RAS and HIF-1a) under MCT-1 oncogenic stress
could increase cancer cell growth and angiogenecity that
are substantially advantageous for tumor development
(Additional file 3). The MDM2-p53 pathway has been
recognized as an ideal therapeutic target for cancer
treatment [55]. MCT-1 promotes angiogenesis that
might be achieved by deregulating p53 downstream tar-
gets, such as, TSP1, VEGF, and COX-2 [56-58]; by inhi-
biting the MDM2-HIF-1a interaction [59,60]; or by
enhancing the Twist-HIF-1a regulation [53]. Under-
standing of the crosstalk between MCT-1 and p53 in
depth may facilitate the development of a new promis-
ing cancer therapeutic strategy that improves the thera-
peutic efficacy.
How do MCT-1 and p53 counteract each other?
MCT-1 modulates p53 degradation through the extra-
cellular signal-regulated kinase activity (ERK) because
the ERK antagonist effectively restores p53-p21 expres-
sion [35]. In a negative feedback loop, p53 may deacti-
vate ERK function to change MCT-1 stability [27]. Our
important novel findings indicate that the S118A mutant
of MCT-1 fails to inhibit p53 promoter activity but that
is still affected by the mimetic ERK-phosphorylated
MCT-1 (S118E and S118D) (Figure 4H). For that rea-
son, MCT-1 could regulate the p53 gene promoter
involving ERK pathway, or direct interaction with ERK
molecule [27,35]. In addition, p53 regulates and
represses RNA poly III transcription activity that may
control MCT-1 protein synthesis or the oncogenic
effects on cell growth as the literatures indicate [61,62].
MCT-1 may also functionally resemble E6 and MDM2
oncoproteins, releasing RNA poly III from repression by
p53 that highly enhances pol III transcription activity
for protein synthesis, cell growth, and malignant pheno-
types [63,64].
Conclusions
Our results uncover an important reciprocated regula-
tion between MCT-1 oncogene and p53 tumor suppres-
sor. Achieving a counterbalance between them may
determine tumor prevention or development. The wild-
type p53 gene reactivation is not capable to suppress the
tumor growth promoted by MCT-1. Thus, MCT-1 gene
knockout or dysfunction of MCT-1 activity could be
another significant stratagem for inhibition of the
tumorigenicity.
Methods
Antibodies and reagents
Antibodies (Abs) against the following proteins were pur-
chased from different sources as indicated: p53, p21,
Cop1, Pirh2, integrin-b4 and AKT (Santa Cruz Biotech-
nology, Santa Cruz, CA); MDM2, a-tubulin, GAPDH and
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b-actin (Abcam, Cambridge, UK); phospho-MAPK
(Thr202/Tyr204), phospho-AKT (Ser473), phospho-p53
(Ser15) and MAPK (Cell Signaling Technology, Danvers,
MA); and CD31 (BD Pharmingen, San Diego, CA). The
V5-epitope Ab (Invitrogen, Carlsbad, CA) identified the
ectopically expressed V5-tagged MCT-1. The MCT-1 rab-
bit antibody (Zymed Laboratories Inc, San Francisco, CA)
for detecting intrinsic MCT-1 was generated against a syn-
thetic peptide (a.a. 72-88). Actinomycin-D and etoposide
were acquired from Sigma (St. Louis, MO). pCMV-p53
and pCMV-p53mt135 plasmid DNA were obtained from
Clontech Laboratories Inc. (Mountain View, CA).
Cell culture and transfections
Non-small cell lung cancer cells, H1299 (p53 null) were
co-transfected with pLXSN/MCT-1-V5 and pCDNA3.1/
p53. Another lung cancer cell line A549 (p53 will-type)
was transfected with pLXSN vector alone or pLXSN/
MCT-1-V5. The stable master cultures were established
and maintained as previously described [35]. Normal
breast epithelial MCF-10A cells were transfected with
pLXSN or pLXSN/MCT-1-V5 that subsequently trans-
fected with pMKO.1 puro p53 short hairpin RNA2
(shRNA2) or a mock vector as previously described [36].
The MCT-1 gene was abrogated in parental H1299 or
MCF-10A cells by transfection with the pGeneClip
MCTS1 shRNA vector (SA Biosciences Corp, Frederick,
MD), using jetPEI™transfection reagent (Polyplus-transfec-
tion, New York, NY). These stable transfectants were cul-
tured with the medium containing puromycin (0.5 μg/ml).
Quantitative real-time polymerase chain reaction (qRT-
PCR)
Total RNA was extracted from cells or mouse tumor tis-
sues using TRIzol reagent (Invitrogen). The cDNA was
synthesized from 2 μg RNA using Oligo (dT)12-18 primer
and Superscript II reverse transcriptase (Invitrogen).
MCT-1 mRNA levels were measured as previously
described [36]. The specific primers for p53, MDM2,
Cop1, Pirh2, HIF-1a and H-Ras genes were designed by
Primer Express software to ensure a single 72, 99, 123,
137, 76 and 69-bp amplicon. These probes were labeled
NFQ (quencher) and FAM (reporter) and synthesized by
Integrated DNA Technologies (Applied Biosystems, Fos-
ter City, CA). Reactions were performed in a 20 μl reac-
tion mixture containing 150 ng cDNA, 10 μl TaqMan
PCR Master Mix (Applied Biosystems) and 1 μl corre-
sponding TaqMan probe. Reactions were run on the
ABI Prism 7900 Fast Real-Time PCR system in triplicate
as follows: 95°C for 10 min, 45 cycles of a 15-second
denaturing at 95°C and 1 min annealing at 60°C. The
mRNA levels were calculated. Cycle threshold (ΔCt) =
Ct target gene - Ct endogenous control (18S rRNA
gene).
Plasmid construction
MCT-1 promoter DNA was isolated from the MCF-10A
genome by PCR amplification using the forward primer,
5’-GAGCGGTACCAGGTTTTTAAATTTTT-3’ (-1301
to -1284), and the reverse primer, 5’-GGAAGCTTT-
TAGGCAACCGG-3’ (+37 to +25). The PCR products
were cloned into KpnI and HindIII restriction sites of
pGL3-Luciferase basic vector (pGL3-MCT-1 promoter).
The p53 promoter segment (-188 to +23) was amplified
by PCR using the forward primer, 5’-CGAGCTCGT
CGGCGAGAATCCTGACT-3’ (-188 to -170), and the
reverse primer, 5’-GGAAGCTTGGACGGTGGCTCTA
GACTTT-3’ (+3 to +23). The PCR products were con-
structed in the pGL3-Luciferase basic vector with SacI
and HindIII restriction sites (pGL3-p53 promoter). The
5’LTR promoter of the pLXSN vector was PCR-ampli-
fied with the primers 5’-GGGGTACCTAGACCACTC-
TACCCTATTC-3’ and 5’-CCAAGCTTACACCC
TAACTGACACACAT-3’ to respectively generate KpnI
and HindIII sites at the 5’-and 3’-ends of the DNA frag-
ment. The amplified 5’LTR promoter was cloned into
the pGL3-Luciferase basic vector using KpnI and Hin-
dIII sites (pGL3-5’LTR).
The CMV promoter was removed from pCDNA3.1
(+)/hygro vector using MluI and NheI and inserted into
the pGL3-Luciferase basic vector with the same restric-
tion sites to generate the CMV reporter construct
(pGL3-CMV).
Site-directed mutagenesis on MCT-1
Three PCR primer sets were designed to generate the
mutant strands of MCT-1 on Serine 118 residue (S118).
The primer set for S118A included the forward primer
5’-GTCCAGGCTTAACTGCTCCTGGAGCTAAG-3’
and the reverse primer 5’-CTTAGCTCCAGGAGCAGT-
TAAGCCTGGAC-3’. The primer set for S118D
included the forward primer 5’-CATGTGTCCAGGCT-
TAACTGACCCTGGAGCTAAGCTTTAC-3’ and the
reverse primer 5’-GTAAAGCTTAGCTCCAGGGT-
CAGTTAAGCCTGGACACATG-3’. The primer set for
S118E included the forward primer 5’-CATGTGTC-
CAGGCTTAACTGAGCCTGGAGCTAAGCTTTAC-3’
and the reverse primer 5’-GTAAAGCTTAGCTC-
CAGGCTCAGTTAAGCCTGGACACATG-3’. Following
the manufacturer’s protocol for the GeneEditor™in vitro
site-directed mutagenesis system (Promega, Madison,
WI), the insertion of wild-type MCT-1 constructed on
pGEX-5X-1 plasmid was used as the mutagenesis tem-
plate. The plasmid DNA was denatured, phosphorylated,
annealed with the mutagenic oligonucleotides, and incu-
bated with T4 DNA polymerase and T4 DNA ligase
(Promega) at 37°C for 90 min. Mutant plasmids were
transformed into BMH 71-18 mutS competent cells and
selected with the GeneEditor™antibiotic selection mix,
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and subsequently transformed into high-efficiency
JM109 competent cells followed by the selection of the
ampicillin and GeneEditor™antibiotic selection mix. For
long term storage, the mutants were transformed into
the DH5a competent cells.
Wild-type MCT-1 cDNA was digested from pLXSN-
MCT-1 plasmid by EcoRI & XhoI. Point mutant inserts
were digested from pGEX-5X-1-MCT-1 mutant plasmid
by EcoRI and BamHI. Inserts were amplified by pfu
DNA polymerase (Stratagene, La Jolla, CA) using F-
MCT1-Hpa (forward primer 5’-CCCGTTAACGCCAC-
CATGTTCAAGAAATTTGATGAAAAAGAAAATG
TG-3’) and R-MCT1-Cla (reverse primer 5’-CCCATC
GATTTTATTTCAGTTATCTAATTTGCGGCCGCTT
TATATGTCTTCATATG CCACAGCCCATC-3’). PCR
products were digested with HpaI and ClaI before con-
structing into pLHCX vector (BD Biosciences, Palo Alto,
CA). The recombinant plasmids were transformed into
OneShot MachI T1 cells (Invitrogen), followed by col-
ony PCR, enzyme digestion, and sequencing analysis.
Three copies of FLAG Tag was PCR-priming from
pCMV3Tag8 vector (Stratagene) with the FLAG Tag
primer set, i.e. forward primer 5’-ATTTGCGGCCG
CACTCGAGGATTACAAGGAT-3’ and reverse primer
5’-TAAAGCGGCCGCCTATTTATCGTCATC-3’. The
PCR product of three copies of Flag Tag was cloned
into the NotI site of pLHCX-MCT-1 plasmid. MOCK
control (pLHCX vector alone) and FLAG-tagged
pLHCX-MCT-1 (wild-type and mutants) plasmids were
individually transfected into PT67 packaging cell line
(BD Biosciences) using a Lipofectamine agent (Invitro-
gen). Transfectants were selected by 100 μg/ml hygro-
mycin (MD Bio, Taipei, Taiwan). The viral supernatants
were collected in a hygromycin-free medium and then
infected MCF-10A cells (ATCC, Manassas, VA).
Luciferase activity assay
To analyze the luciferase activity, 0.5 μg reporter plas-
mid (pGL3-MCT-1 promoter, pGL3-p53 promoter,
pGL3-5’LTR, or pGL3-CMV), 0.1 μg b-galactosidase
plasmid, and 1 μl JetPEI reagent were mixed with
75 mM NaCl solution for 30 min before transfection
into H1299 or MCF-10A cells. After 48 h, the cells were
washed with 1X PBS and incubated with 200 μl lysis
buffer (Promega) for 30 min at -80°C. Cell extracts
(70 μl) were added into 96-well microtiter plates and
combined with 30 μl luciferase assay reagent (Promega).
The reaction was detected with a Hidex Chameleon
machine, and then analyzed with Mikro Win2000 soft-
ware. To analyze b-galactosidase activity, 30 μl lysates
were incubated with 22 μl 1X ONPG, 47 mM sodium
phosphate, and 1 mM MgCl2 solution. Reactions were
incubated at 37°C for 10 min and measured with the
spectrophotometer at OD 420 nm.
Chromatin immunoprecipitation (ChIP) assay
ChIP experiments were performed according to the man-
ufacturer’s protocol (Upstate Biotechnology, Lake Placid,
NY). MCF-10A (p53 proficient) or p53-restored H1299
(2 × 107) cells were exposed to 40 μM etoposide for 4 h,
fixed with 1% formaldehyde for 10 min at room tempera-
ture, neutralized with 125 mM glycine for 5 min, washed
twice with PBS, and the cells were scraped off with PBS
containing the protease inhibitor cocktail. Cell pellets
were suspended in a 400 μl SDS lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris-HCl, pH 8.0, protease inhibi-
tor cocktail) and incubated on ice for 15 min followed by
shearing of the genomic DNA into 200-1000 bp frag-
ments by a sonicator (Bioruptor UCD-200). After clean-
ing the insoluble materials by centrifugation,
supernatants were diluted with a 900 μl ChIP dilution
buffer (0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 167
mM NaCl, 16.7 mM Tris-HCl, pH 8.1, protease inhibitor
cocktail). Samples were pre-cleared with a 60 μl salmon
sperm DNA/Protein G agarose slurry for 1 h at 4°C. An
aliquot (10 μl) of the supernatants were kept as input
materials, and the remaining samples (990 μl) were
respectively incubated with 2 μg p53 Ab, 2 μg MCT-1
Ab, 1 μg RNA polymerase II Ab (positive control), or
1 μg normal mouse IgG (negative control) for 24 h at 4°
C. The protein-DNA immune complexes were incubated
with 60 μl salmon sperm DNA/Protein G agarose slurry
for 1 h at 4°C. Beads were washed sequentially with the
low salt buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA,
150 mM NaCl, 0.1% SDS, 1% Triton X-100), the high salt
buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 500 mM
NaCl, 0.1% SDS, 1% Triton X-100), the LiCl buffer (250
mM LiCl, 1% IGEPAL-CA630, 1 mM EDTA, 10 mM
Tris-HCl, pH 8.0, 1% deoxycholic acid), and then rinsed
twice with TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM
EDTA). Afterward, the protein-DNA complexes were
eluted from the beads with 1% SDS (200 μl) at room tem-
perature for 15 min. To reverse the cross-linked protein-
DNA complexes, samples were diluted to 50 mM NaCl
followed by incubation with 10 μg RNaseA and 10 μg
proteinase K at 65°C for 24 h. The eluted DNA was puri-
fied with a PCR Purification Kit (Qiagen, Valencia, CA)
and subjected to the conventional PCR and q-PCR. Con-
ventional PCR products were resolved on a 2% agarose
gel and stained with ethidium bromide. For q-PCR analy-
sis, we employed the SYBR green system using the ABI
Prism 7900 Fast Real-Time PCR system and determined
the threshold cycle numbers (Ct). All the relative Ct
values were normalized to the inputs and compared
between samples.
Electrophoretic-mobility shift assay (EMSA)
EMSA was conducted with a Gel-Shift kit according to
the manufacturer’s protocol (Panomics, Fremont, CA).
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The nuclear extracts were prepared after MCF-10A (2 ×
107) cells were exposed to 40 μM etoposide (ETO) for
4 h. The biotin-labeled MCT-1 promoter probes (166,
173 and 199 bp) corresponding to the nucleotides -1301
to -1135, -1142 to -969, and -1000 to -801 on the promo-
ter regions were PCR amplified by forward and reverse
primers as listed (Additional File 2). The PCR-amplified
DNA probes were clarified by gel extraction kit (Qiagen).
Nuclear extracts (5 μg) were pre-incubated with 1X
EMSA binding buffer and 1 μg poly d(I-C) for 5 min at
room temperature followed by incubation with 30 ng of
biotin-labeled MCT-1 probe at 15°C for 30 min. The
competition experiments were performed by including a
100- or 200-fold excess of unlabeled wild-type or mutant
p53 consensus sequences in the reactions for 20 min
prior to incubation with the biotin-labeled probe. For the
super-shift assay, 1 μg of p53 antibody (SC-126 X) (Santa
Cruz) was pre-incubated with the reaction for 1 h prior
to adding the probe. Protein-DNA complexes were
resolved with 6% non-denaturing polyacrylamide gel in
0.5X Tris-borate/EDTA buffer (100 mM Tris, 90 mM
boric acid, 1 mM EDTA) at 4°C and transferred to an
Immobilon positively-charged nylon membrane (Milli-
pore, Billerica, MA) for 1 h at 300 mA. The transferred
oligonucleotides were immobilized by UV crosslinking
for 3 min. The membranes were reacted with the block-
ing buffer followed by reaction with Streptavidin-HRP
and development with ECL reagent.
Cell apoptotic analysis
To evaluate apoptotic cell death, MCF-10A cells were
treated with 5 μM H2O2 or 40 mU Bleomycin for 24 h
followed by staining with a Annexin V apoptosis detec-
tion kit (BD Biosciences) for 15 min. Afterward, apopto-
tic cells were evaluated by BD FACS Calibur Flow
Cytometry (Becton-Dickinson, San Jose, CA).
Cell migration assay
MCF-10A cells were essayed for migratory ability with
QCM™24-Well Fluorimetric Cell Migration Array Kit
(Chemicon International Inc., Temecula, CA). Cells (5 ×
105 cells) were seeded in the culture chamber with an
8 μm pore size polycarbonate membrane. Five hundred
microliter of serum-free or the complete DMEM/F-12
medium was added to the lower chamber. After incubat-
ing for 16 h at 37°C in a CO2 incubator, the non-migratory
cells were carefully removed and the chamber membranes
were inserted into a fresh well with 225 μl pre-warmed
Cell Detachment Solution for 30 min in a 37°C incubator
to detach cells, followed by adding 75 μl Lysis Buffer/
CyQuant GR® dye solution for 15 min at room tempera-
ture. Reaction mixtures (200 μl) were added into a 96-well
micro-titer plate for detection of fluorescence absorbance
at excitation/emission filter sets 485/530 nm using a
Hidex Plate Chameleon (SisLab, Milano, Italy) apparatus.
Tumorigenicity, hemoglobin assay, and
immunohistochemistry studies
Eight-week-old female BALB/c nude mice (BALB/cAnN-
Foxn1nu/CrlNarl) were injected with H1299 cancer cells
(control, MCT-1, control + p53, MCT-1 + p53). This animal
experiment was approved by Animal Use Protocol in
National Health Research Institutes (NHRI-IACUC-096049-
A). Each mouse was inoculated with 2 × 106 cells suspended
in 100 μl RPMI medium at both subcutaneous sites. When
tumor sizes had reached approximately 4-6 mm, the tumors
were resected and weighed. The portions of tumor tissues
were processed for hemoglobin levels, immunoblotting,
qRT-PCR, and immunohistochemistry analysis as previously
described [36].
Additional material
Additional file 1: Luciferase activity of the pGL3-5’LTR (pLXSN)
promoter and the pGL3-CMV (pCDNA3.1) promoter in H1299 cells.
(A) There were no significant changes of 5’LTR promoter (pLXSN vector)
activity in the presence or absence of p53. (B) Ectopic expression of
MCT-1 did not affect CMV (pCDNA vector) promoter activity in either
p53-null or p53-positive conditions.
Additional file 2: Sequences of the primers, the probes, and the
competitors. Lists of primer sequences used for ChIP and EMSA assays,
as well the nucleotide sequence of wild-type and the site-specific
mutant of p53-responsive elements used for the EMSA competition
assays.
Additional file 3: Oncogenic molecules are promoted in the MCT-1
xenograft tumors. (A) The significant elevations of integrin-b4, p-AKT,
and p-MAPK proteins were particularly recognizable in the MCT-1 + p53
tumors, whereas these proteins were rather reduced in other types of
xenograft tumors (control, MCT-1, and control + p53). (B) The expressions
of H-Ras and HIF-1a genes, potentially relating to cell malignancy, were
promoting in the MCT-1 + p53 xenograft tumors.
List of abbreviations
MCT-1: multiple copies in T-cell malignancy 1; bp: base pair; mRNA:
messenger RNA; shRNA: short hairpin RNA; NFQ: non-fluorescent quencher;
FAM: 5-carboxyfluorescein; PBS: phosphate-buffered saline; HRP: horseradish
peroxidase; ChIP: chromatin immunoprecipitation; EMSA: electrophoretic
mobility shift assay; qRT-PCR: quantitative real-time polymerase chain
reaction; Luc: firefly luciferase; Ab: antibody; min: minute; H&E: hematoxylin
and eosin; ECL: enhanced chemiluminescence; ETO: etoposide.
Acknowledgements
This work was funded by National Health Research Institutes (98A1-MGPP06-
014), National Science Council (NSC 96-2628-B-400-003-MY3; NSC 98-3112-B-
400-008), and partially supported by DOH99-TD-C-111-004 grants. This
research was also conducted under the Graduate Program of Biotechnology
in Medicine sponsored by the National Tsing Hua University and the
National Health Research Institutes.
Author details
1Division of Molecular and Genomic Medicine, National Health Research
Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan. 2Institute of
Molecular Medicine, National Tsing Hua University, Hsinchu 300, Taiwan.
Kasiappan et al. Molecular Cancer 2010, 9:311
http://www.molecular-cancer.com/content/9/1/311
Page 15 of 17
Authors’ contributions
RK performed q-RT-PCR, CHIP, EMSA, cloning, luciferase, Western blotting,
animal experiments, and sketched the manuscript. HJS performed gene
silencing, DNA cloning, Western blotting, and cell migration analysis. MHW
performed the cell cycle profiling study. COC performed apoptotic analysis.
TDL helped with luciferase reporter assays in MCT-1 mutants. LC did
immunohistochemistry study. HLH supported and supervised the entire
project, interpreted data, and approved publication after critically revising
the manuscript. All authors have read and approved the final paper.
Competing interests
The authors declare that they have no competing interests
Received: 22 August 2010 Accepted: 7 December 2010
Published: 7 December 2010
References
1. Sherr CJ: Principles of tumor suppression. Cell 2004, 116:235-246.
2. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control.
Nat Med 2004, 10:789-799.
3. Soussi T, Lozano G: p53 mutation heterogeneity in cancer. Biochem
Biophys Res Commun 2005, 331:834-842.
4. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000,
408:307-310.
5. Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol
2007, 8:275-283.
6. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a
consensus binding site for p53. Nat Genet 1992, 1:45-49.
7. Gottlieb TM, Oren M: p53 in growth control and neoplasia. Biochim
Biophys Acta 1996, 1287:77-102.
8. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997,
88:323-331.
9. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G,
Hakem R, Benchimol S: Pirh2, a p53-induced ubiquitin-protein ligase,
promotes p53 degradation. Cell 2003, 112:779-791.
10. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O’Rourke K,
Koeppen H, Dixit VM: The ubiquitin ligase COP1 is a critical negative
regulator of p53. Nature 2004, 429:86-92.
11. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D,
Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53
tumor suppression. Cell 1993, 75:817-825.
12. Barak Y, Juven T, Haffner R, Oren M: mdm2 expression is induced by wild
type p53 activity. EMBO J 1993, 12:461-468.
13. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional
activator of the human bax gene. Cell 1995, 80:293-299.
14. Morris GF, Bischoff JR, Mathews MB: Transcriptional activation of the
human proliferating-cell nuclear antigen promoter by p53. Proc Natl
Acad Sci USA 1996, 93:895-899.
15. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W: Mono- versus
polyubiquitination: differential control of p53 fate by Mdm2. Science
2003, 302:1972-1975.
16. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D,
Piccolboni A, Sementchenko V, Cheng J, Williams AJ, et al: Unbiased
mapping of transcription factor binding sites along human
chromosomes 21 and 22 points to widespread regulation of noncoding
RNAs. Cell 2004, 116:499-509.
17. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y,
Weng Z, et al: A global map of p53 transcription-factor binding sites in
the human genome. Cell 2006, 124:207-219.
18. Kim E, Giese A, Deppert W: Wild-type p53 in cancer cells: when a
guardian turns into a blackguard. Biochem Pharmacol 2009, 77:11-20.
19. Janicke RU, Sohn D, Schulze-Osthoff K: The dark side of a tumor
suppressor: anti-apoptotic p53. Cell Death Differ 2008, 15:959-976.
20. Sharpless NE, DePinho RA: p53: good cop/bad cop. Cell 2002, 110:9-12.
21. Vousden KH: Outcomes of p53 activation–spoilt for choice. J Cell Sci 2006,
119:5015-5020.
22. Essmann F, Pohlmann S, Gillissen B, Daniel PT, Schulze-Osthoff K,
Janicke RU: Irradiation-induced translocation of p53 to mitochondria in
the absence of apoptosis. J Biol Chem 2005, 280:37169-37177.
23. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM:
Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of
bacterial AhpD. Science 2004, 304:596-600.
24. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE,
Chumakov PM: The antioxidant function of the p53 tumor suppressor.
Nat Med 2005, 11:1306-1313.
25. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E,
Vousden KH: TIGAR, a p53-inducible regulator of glycolysis and
apoptosis. Cell 2006, 126:107-120.
26. Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB: Expression of the
candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies.
Blood 2003, 102:297-302.
27. Dai B, Zhao XF, Hagner P, Shapiro P, Mazan-Mamczarz K, Zhao S,
Natkunam Y, Gartenhaus RB: Extracellular signal-regulated kinase
positively regulates the oncogenic activity of MCT-1 in diffuse large B-
cell lymphoma. Cancer Res 2009, 69:7835-7843.
28. Dierov J, Prosniak M, Gallia G, Gartenhaus RB: Increased G1 cyclin/cdk
activity in cells overexpressing the candidate oncogene, MCT-1. J Cell
Biochem 1999, 74:544-550.
29. Prosniak M, Dierov J, Okami K, Tilton B, Jameson B, Sawaya BE,
Gartenhaus RB: A novel candidate oncogene, MCT-1, is involved in cell
cycle progression. Cancer Res 1998, 58:4233-4237.
30. Hsu HL, Shi B, Gartenhaus RB: The MCT-1 oncogene product impairs cell
cycle checkpoint control and transforms human mammary epithelial
cells. Oncogene 2005, 24:4956-4964.
31. Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C,
Jordan VC, Volpert OV, Satcher RL, Gartenhaus RB: MCT-1 oncogene
contributes to increased in vivo tumorigenicity of MCF7 cells by
promotion of angiogenesis and inhibition of apoptosis. Cancer Res 2005,
65:10651-10656.
32. Fleischer TC, Weaver CM, McAfee KJ, Jennings JL, Link AJ: Systematic
identification and functional screens of uncharacterized proteins
associated with eukaryotic ribosomal complexes. Genes Dev 2006,
20:1294-1307.
33. Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG,
Gorospe M, Keene JD, Levenson AS, Gartenhaus RB: Post-transcriptional
gene regulation by HuR promotes a more tumorigenic phenotype.
Oncogene 2008, 27:6151-6163.
34. Reinert LS, Shi B, Nandi S, Mazan-Mamczarz K, Vitolo M, Bachman KE, He H,
Gartenhaus RB: MCT-1 protein interacts with the cap complex and
modulates messenger RNA translational profiles. Cancer Res 2006,
66:8994-9001.
35. Hsu HL, Choy CO, Kasiappan R, Shih HJ, Sawyer JR, Shu CL, Chu KL,
Chen YR, Hsu HF, Gartenhaus RB: MCT-1 oncogene downregulates p53
and destabilizes genome structure in the response to DNA double-
strand damage. DNA Repair (Amst) 2007, 6:1319-1332.
36. Kasiappan R, Shih HJ, Chu KL, Chen WT, Liu HP, Huang SF, Choy CO,
Shu CL, Din R, Chu JS, Hsu HL: Loss of p53 and MCT-1 overexpression
synergistically promote chromosome instability and tumorigenicity. Mol
Cancer Res 2009, 7:536-548.
37. Wang S, El-Deiry WS: p73 or p53 directly regulates human p53
transcription to maintain cell cycle checkpoints. Cancer Res 2006,
66:6982-6989.
38. Sun X, Shimizu H, Yamamoto K: Identification of a novel p53 promoter
element involved in genotoxic stress-inducible p53 gene expression. Mol
Cell Biol 1995, 15:4489-4496.
39. Roger L, Gadea G, Roux P: Control of cell migration: a tumour suppressor
function for p53? Biol Cell 2006, 98:141-152, Review.
40. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid
degradation of p53. Nature 1997, 387:296-299.
41. Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H,
Dixit VM, French DM: COP1, the negative regulator of p53, is
overexpressed in breast and ovarian adenocarcinomas. Cancer Res 2004,
64:7226-7230.
42. Ganguli G, Wasylyk B: p53-independent functions of MDM2. Mol Cancer
Res 2003, 1:1027-1035.
43. Wang XM, Yang LY, Guo L, Fan C, Wu F: p53-induced RING-H2 protein, a
novel marker for poor survival in hepatocellular carcinoma after hepatic
resection. Cancer 2009, 115:4554-4563.
Kasiappan et al. Molecular Cancer 2010, 9:311
http://www.molecular-cancer.com/content/9/1/311
Page 16 of 17
44. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2
oncogene product forms a complex with the p53 protein and inhibits
p53-mediated transactivation. Cell 1992, 69:1237-1245.
45. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory
feedback loop. Genes Dev 1993, 7:1126-1132.
46. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Hirano G,
Takahashi M, Naito S, Kohno K: Twist and p53 reciprocally regulate target
genes via direct interaction. Oncogene 2008, 27:5543-5553.
47. Kim MK, Carroll WL: Autoregulation of the N-myc gene is operative in
neuroblastoma and involves histone deacetylase 2. Cancer 2004,
101:2106-2115.
48. Sivak LE, Tai KF, Smith RS, Dillon PA, Brodeur GM, Carroll WL:
Autoregulation of the human N-myc oncogene is disrupted in amplified
but not single-copy neuroblastoma cell lines. Oncogene 1997,
15:1937-1946.
49. Weaver BA, Cleveland DW: Does aneuploidy cause cancer? Curr Opin Cell
Biol 2006, 18:658-667.
50. Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG: Integrin beta4
signaling promotes tumor angiogenesis. Cancer Cell 2004, 6:471-483.
51. Giehl K: Oncogenic Ras in tumour progression and metastasis. Biol Chem
2005, 386:193-205.
52. Yang MH, Wu KJ: TWIST activation by hypoxia inducible factor-1 (HIF-1):
implications in metastasis and development. Cell Cycle 2008, 7:2090-2096.
53. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ:
Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell
Biol 2008, 10:295-305.
54. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D,
Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of
hypoxia-inducible factor 1alpha in common human cancers and their
metastases. Cancer Res 1999, 59:5830-5835.
55. Shangary S, Wang S: Targeting the MDM2-p53 interaction for cancer
therapy. Clin Cancer Res 2008, 14:5318-5324.
56. Duarte ML, de Moraes E, Pontes E, Schluckebier L, de Moraes JL, Hainaut P,
Ferreira CG: Role of p53 in the induction of cyclooxygenase-2 by
cisplatin or paclitaxel in non-small cell lung cancer cell lines. Cancer Lett
2009, 279:57-64.
57. el-Deiry WS: Regulation of p53 downstream genes. Semin Cancer Biol
1998, 8:345-357.
58. de Moraes E, Dar NA, de Moura Gallo CV, Hainaut P: Cross-talks between
cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and
death during inflammatory stress and carcinogenesis. Int J Cancer 2007,
121:929-937.
59. Nieminen AL, Qanungo S, Schneider EA, Jiang BH, Agani FH: Mdm2 and
HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 2005,
204:364-369.
60. Carroll VA, Ashcroft M: Regulation of angiogenic factors by HDM2 in renal
cell carcinoma. Cancer Res 2008, 68:545-552.
61. Cairns CA, White RJ: p53 is a general repressor of RNA polymerase III
transcription. EMBO J 1998, 17:3112-3123.
62. Felton-Edkins ZA, Kenneth NS, Brown TR, Daly NL, Gomez-Roman N,
Grandori C, Eisenman RN, White RJ: Direct regulation of RNA polymerase
III transcription by RB, p53 and c-Myc. Cell Cycle 2003, 2:181-184.
63. Stein T, Crighton D, Boyle JM, Varley JM, White RJ: RNA polymerase III
transcription can be derepressed by oncogenes or mutations that
compromise p53 function in tumours and Li-Fraumeni syndrome.
Oncogene 2002, 21:2961-2970.
64. White RJ: RNA polymerase III transcription and cancer. Oncogene 2004,
23:3208-3216.
doi:10.1186/1476-4598-9-311
Cite this article as: Kasiappan et al.: The antagonism between MCT-1
and p53 affects the tumorigenic outcomes. Molecular Cancer 2010 9:311.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kasiappan et al. Molecular Cancer 2010, 9:311
http://www.molecular-cancer.com/content/9/1/311
Page 17 of 17
